Previous 10 | Next 10 |
home / stock / jnj / jnj articles
Sentiment will likely reverse course, with the index futures trading notably lower early Wednesday. The recent run-up ideally should render the moo...
With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street...
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, with the index remaining in the “Greed” zon...
Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial bu...
SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnolog...
The second-quarter reporting season got off to a rocky start with investors reacting to some big bank earnings. Nevertheless, optimism over a healt...
U.S. pharma giant Johnson & Johnson (NYSE:JNJ) will report its second-quarter 2024 earnings on Wednesday, July 17. As per data from Benzinga Pr...
Johnson and Johnson (NYSE:JNJ) shares are trending on Friday. In the last week, the pharmaceutical company announced positive results from two clin...
On Tuesday, Johnson & Johnson (NYSE:JNJ) announced results from a prespecified second interim analysis of Phase 3 CARTITUDE-4 study evaluating...
News, Short Squeeze, Breakout and More Instantly...
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with tr...
2024-07-18 11:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 05:40:00 ET On July 17, Johnson & Johnson (NYSE: JNJ) announced second-quarter results that gave investors a lot to look forward to. Integration of newly acquired medical technology plus upcoming expansions of patent-protected medicines will help push the healthcare c...